Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. MAIT cell subtypes in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

We characterized naïve, central memory (CM), effector memory (EM) and terminally differentiated effector memory (TEMRA) CD4+ and CD8+ T cells and their expression of CD49d and CD26 in peripheral blood in patients with multiple sclerosis (MS) and healthy controls. CD26+ CD28+ CD4+ TEMRA T cells were increased in all subtypes of MS, and CD26+ CD28+ CD8+ TEMRA T cells were increased in relapsing-remitting and secondary progressive MS. Conversely, in progressive MS, CD49d+ CM T cells were decreased and natalizumab increased the circulating number of all six subsets but reduced the frequency of most subsets expressing CD49d and CD26.

OriginalsprogEngelsk
TidsskriftJournal of Neuroimmunology
Vol/bind310
Sider (fra-til)17-25
Antal sider9
ISSN0165-5728
DOI
StatusUdgivet - 15 sep. 2017

ID: 52217545